American Heart Journal
Volume 141, Issue 2, Supplement , Pages S22-S25, February 2001

Drug therapy or coronary angioplasty for the treatment of coronary artery disease: New insights

University Hospital of Groningen. Groningen, The Netherlands

Abstract 

Background In the last decade percutaneous transluminal coronary angioplasty has become a very popular strategy for the treatment of coronary artery disease, although its efficacy in reducing ischemic events and the subsequent need for revascularization has yet to be proved. Methods We reviewed the latest trials that compared percutaneous transluminal coronary angioplasty and medical therapy. Results We discuss the potentially favorable effect of lipid-lowering therapy on coronary atherosclerosis and cardiac events and comment on the results of the recent Atorvastatin Versus Revascularization Treatments (AVERT) study that compared lipid-lowering treatment and percutaneous transluminal coronary angioplasty in patients with stable coronary artery disease. Conclusions Medical treatment aimed at reversing plaque growth and promoting plaque stabilization should probably be considered as the initial therapeutic option. Statin class drugs, together with aggressive management of known risk factors, show promise as the first step after appropriate early diagnosis. Revascularization procedures should subsequently be considered for all patients who do not respond to medical treatment or in whom the disease shows clear signs of progression. (Am Heart J 2001;141:S22-5.)

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Reprint requests: Giovanni Amoroso, MD, Thoraxcentre, Academisch Ziekenhuis Groningen, Postbus 30 001, 9700 RB Groningen, The Netherlands. E-mail: G.Amoroso@thorax.azg.nl

PII: S0002-8703(01)70040-3

American Heart Journal
Volume 141, Issue 2, Supplement , Pages S22-S25, February 2001